A pharma label is not read the way a food or cosmetic label is. A patient or pharmacist scans it fast, often under pressure, and a small error in what they read can lead to a wrong dose or a missed warning. That is why drug labelling in India carries its own dedicated rulebook, separate from general packaging law. It sits under Rule 96 of the Drugs and Cosmetics Rules, 1945, enforced by the Central Drugs Standard Control Organization. Most compliance failures are not big, obvious mistakes. They are small print details that people overlook between the approved artwork and the final printed label. Here are some pointers to note to ensure that your label is as per the pharma label compliance in India.
The Generic Name Has to Dominate, Not the Brand Name
This is the rule brands underestimate most. On an Indian drug label, the generic name must appear more prominently than the brand name. It should be immediately above or below it, and in a font size that meets a minimum size relative to the brand name text. Marketing instinct pulls in the opposite direction, since brand names are what companies want to stand out. But pharma label compliance cares about generic name visibility. It is what tells a pharmacist or doctor what the drug actually is, regardless of which company made it. A label that looks fine from a design standpoint can still fail this rule if the generic name was sized to match the brand name instead of dominate it.
Schedule H, H1, and X Drugs Carry Extra Warning Requirements
Not all drugs follow the same labelling rules. Schedule H drugs need a clear statement that they cannot be sold without a prescription. These drugs go further, requiring a red vertical line or box on the label along with a specific warning about prescription-only sale. This is because this schedule covers habit-forming and antibiotic-resistant medicines that need tighter control. And, Schedule X applies to narcotic and psychotropic substances and carries its own set of restrictions. Getting the wrong schedule’s warning format on a label, or missing the schedule-specific symbol entirely, is a compliance failure. It can also trigger a recall even if every other detail on the label is correct.
Batch Numbers and Expiry Dates Have to Survive the Full Shelf Life
A batch number and expiry date are not just information. They are the backbone of pharma traceability. They need to stay legible for the entire time a product sits on a shelf or in a medicine cabinet, not just at the point of packing. A label or ink that fades or becomes hard to read after a few months undermines this system quietly. If a batch has to be recalled and the number on the pack is unreadable, that failure traces back to a print or material choice made long before the recall, not to anything the pharmacy or patient did wrong.
Storage Conditions and Manufacturing Details Cannot Be Rounded Off
One needs to print storage instructions, manufacturing license numbers, and manufacturer details exactly as approved, without shorthand or rounding for space. A temperature range for storage, for example, needs to appear in full, since pharmacists as well as patients rely on it to store a drug correctly. Space pressure on smaller pack sizes sometimes tempts a design team to abbreviate this information. That instinct works fine for a consumer product. It does not work for a drug label, where the abbreviated version can fall outside what CDSCO actually approved.
Compliance Does Not End at Approval
CDSCO rules are also not static. A June 2026 amendment to Schedule V changed the unit of measurement required for folic acid labelling. It’s a small but real reminder that approved artwork from even a year ago is not guaranteed to still be compliant today. Pharma brands and their print partners need to treat every reprint as a chance to check the label against current rules. That habit is what actually prevents the more serious outcomes. A labelling failure at this level does not stop at a fine. It can mean a product recall, a blocked import at customs, or in serious cases, a loss of the manufacturing license itself.
FAQs
What is Rule 96 in Indian drug labeling?
Rule 96 of the Drugs and Cosmetics Rules, 1945 sets out the mandatory labelling requirements for drugs sold in India. It includes generic name prominence, batch and also expiry details, manufacturer information, and storage instructions.
Why must the generic name be more prominent than the brand name on drug labels?
Regulators require this so that pharmacists and doctors can identify the actual drug regardless of brand. It matters for substitution, dosage accuracy, and patient safety. The generic name must appear immediately next to the brand name and meet a minimum size relative to it.
What makes Schedule H1 drug labels different from standard drug labels?
Schedule H1 drugs include certain habit-forming and antibiotic-resistant medicines. They require a red vertical line or box on the label along with a specific prescription-only warning, in addition to standard labelling requirements.
What happens if a pharma label fails CDSCO compliance?
Consequences can include a mandated product recall, blocked entry at customs for imported drugs, financial penalties. In serious cases, suspension or cancellation of the manufacturing or import license can also be done.
